Recombinant Strain | Model | Strategy/Result | Reference |
---|---|---|---|
C. oncolyticum/sporogenesrecombinant for E. coli colicin E3 | In vitro study | Cancerostatic properties | [56] |
C. beijerinckii (acetobutylicum) recombinant for E. coli cytosine deaminase (CDase) | In vitro study and tested on murine EMT6 carcinoma cell-line | Sensitivity to 5-fluorocytosine increased 500-fold | [72] |
C. beijerinckii (acetobutylicum) recombinant for Nitroreductase (NTR) | EMT6 Mouse Prodrug: CB1954 | CDEPT strategy with CB1954 Nitroreductase activity detected in tumor lysate | [54] |
C. acetobutylicum recombinant for Tumour necrosis factor (TNF-α) | Rhabdomyosarcoma | Recombinant protein detected in tumour, but no control of tumour growth | [58] |
C. acetobutylicum recombinant for E. coli cytosine deaminase (CDase) | Rhabdomyosarcoma Prodrug: 5-FC | CDEPT strategy Cytosine deaminase activity detected in tumor lysate | [64] |
C. sporogenes recombinant for cytosine deaminase (CDase) | SCCVII tumours into syngeneic C3H/Km mice Prodrug 5-FC | Growth delay of tumours | [57] |
C. acetobutylicum recombinant for interleukin-2 (IL-2) | Rhabdomyosarcoma | Enhanced antitumour effect | [60 |
C. sporogenes and C. novyi-NT recombinant for Nitroreductase (NTR) | Human colorectal carcinoma (HCT116) | CDEPT strategy with CB1954 High level of colonization 108–109 cfu/g tumour. Repeated CDEPT treatment cycle, significant tumour growth delay | [61] |